Coya Therapeutics Management
Management criteria checks 1/4
Coya Therapeutics' CEO is Arun Swaminathan, appointed in Nov 2024, has a tenure of 1.5 years. total yearly compensation is $2.09M, comprised of 26.1% salary and 73.9% bonuses, including company stock and options. directly owns 0.043% of the company’s shares, worth $42.60K. The average tenure of the management team and the board of directors is 2.2 years and 2.8 years respectively.
Key information
Arun Swaminathan
Chief executive officer
US$2.1m
Total compensation
| CEO salary percentage | 26.11% |
| CEO tenure | 1.5yrs |
| CEO ownership | 0.04% |
| Management average tenure | 2.2yrs |
| Board average tenure | 2.8yrs |
Recent management updates
Recent updates
Is Coya Therapeutics (NASDAQ:COYA) In A Good Position To Invest In Growth?
Sep 16
We Think Coya Therapeutics (NASDAQ:COYA) Can Afford To Drive Business Growth
Apr 04Companies Like Coya Therapeutics (NASDAQ:COYA) Can Afford To Invest In Growth
Oct 29Coya Therapeutics Has Several Near-Term Share Price Appreciation Catalysts
Oct 13Coya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth Plans
Mar 26Coya Therapeutics In Catbird Seat Following Dr. Reddy's Licensing Deal
Feb 13Coya Therapeutics: Interesting Early Data In CNS Diseases, Very Low Cash Position
Jan 13We Think Coya Therapeutics (NASDAQ:COYA) Needs To Drive Business Growth Carefully
Sep 06Here's Why We're Watching Coya Therapeutics' (NASDAQ:COYA) Cash Burn Situation
May 17CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | US$2m | US$546k | -US$21m |
| Sep 30 2025 | n/a | n/a | -US$18m |
| Jun 30 2025 | n/a | n/a | -US$20m |
| Mar 31 2025 | n/a | n/a | -US$17m |
| Dec 31 2024 | US$1m | US$442k | -US$15m |
Compensation vs Market: Arun's total compensation ($USD2.09M) is above average for companies of similar size in the US market ($USD618.00K).
Compensation vs Earnings: Arun's compensation has increased whilst the company is unprofitable.
CEO
Arun Swaminathan (55 yo)
Dr. Arun Swaminathan, Ph.D. is Chief Executive Officer of Coya Therapeutics, Inc. from November 1, 2024 and serves as its Director since August 2024. Dr. Swaminathan was Chief Business Officer of Coya Ther...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.5yrs | US$2.09m | 0.043% $ 42.6k | |
| President & Chief Medical Officer | 2.8yrs | US$1.46m | 0.012% $ 11.5k | |
| CFO & COO | 4.2yrs | US$1.37m | 0.038% $ 37.5k | |
| Head of Neuroinflammation Platform | no data | no data | no data | |
| Senior Vice President of Regulatory | no data | no data | no data | |
| Senior VP of Program Management & Clinical Operations | 1.6yrs | no data | no data |
Experienced Management: COYA's management team is considered experienced (2.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.8yrs | US$2.09m | 0.043% $ 42.6k | |
| Independent Director | 5.2yrs | US$109.02k | 0.12% $ 117.4k | |
| Independent Director | 2.5yrs | US$85.27k | 0.70% $ 703.0k | |
| Director | less than a year | no data | no data | |
| Independent Director | 4.9yrs | US$97.77k | 0.075% $ 74.5k | |
| Clinical Advisor | 2.8yrs | no data | no data | |
| Independent Director | 2.8yrs | US$98.52k | 0% $ 0 | |
| Independent Director | 5yrs | US$99.02k | 0.043% $ 42.6k |
Experienced Board: COYA's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/05 22:28 |
| End of Day Share Price | 2026/05/05 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Coya Therapeutics, Inc. is covered by 8 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Thomas Shrader | BTIG |
| Keay Nakae | Chardan Capital Markets, LLC |
| Jason Kolbert | D. Boral Capital LLC. |